Therapeutic criteria in the acute coronary syndrome [3];Criterios terapéuticos en el síndrome coronario agudo

Revista Clinica Espanola

Volumn 204, Issue 7, 2004, Pages 389-390

  Borja Villegas, J ^a   Rigau Comas, D ^a   Izquierdo Pulido, I ^a  

^a Unidad de Investigacion   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CLOPIDOGREL; ENOXAPARIN; TINZAPARIN;

ACUTE DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INTERMITTENT CLAUDICATION; LETTER; TREATMENT PLANNING;

EID: 4043114826     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: 10.1157/13063537     Document Type: Letter

References (10)

1. Jiménez Mena M, Gómez Bueno M. Criterios terapéuticos en el síndrome coronario agudo. Rev Clin Esp 2003;203:631-42.
2. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
3. Braunwald E, Antman EM, Beasley MD, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA 2002 Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction. Disponible en: http://www.acc.org/clinical/guidelines/unstable/unstable.pdf (Consultado el 5 de marzo de 2003).
4. López Bescós L, Arós Borau F, Lidón Corbi RM, Cequier Fillat A, Bueno H, Alonso JJ, et al. Actualización (2002) de las guías de práctica clínica de la Sociedad Española de Cardiología en angina inestable/infarto sin elevación del segmento ST. Rev Esp Cardiol 2002;55:631-42.
5. Cohen M, Demers C, Gurfinkel EP, Turpie A GG, Fromell GJ, Goodman S, et al, for the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Events Study Group. A comparison of low-molecular-weight heparin with unfractioned heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-52.
6. Antman EM, McCabe CH, Gurfinkel EP, Turpie AGG, Bernink PJ, Salein D, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolisis in myocardial infarction (TIMI) 11B trial. Circulation 1999;100: 1593-601.
7. Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie AGG, et al, for the FRIC investigators. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation 1997;96:61-8.
8. The FRAXIS Study Group. Comparison of two treatment duration (6 days and 14 days) of a low molecular weight heparin with a 6 day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAXIS (FRAXiparine in Ischemic Syndrome). Eur Heart J 1999;20:1553-62.
9. Michalis LK, Papamichael ND, Katsouras CS, Karahaliou A, Sourla E, Novas J, et al. Enoxaparin versus tinzaparin in the management of unstable coronary artery disease (EVET study). J Am Coll Cardiol 2001;37(Suppl 1): 365 A.
10. Papamichael ND, Michalis LK, Katsouras CS, Adamidis K, Sourla E, Sioros L, et al. Enoxaparin versus tinzaparin in unstable coronary syndromes. A head-to-head comparison (EVET trial). Eur Heart J 2001;22(Abstract Suppl):664.